Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LENZ NASDAQ:NRXP NASDAQ:PEPG NASDAQ:RNXT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLENZLENZ Therapeutics$5.48+8.5%$6.26$4.68▼$50.40$171.82M0.621.07 million shs1.43 million shsNRXPNRx Pharmaceuticals$3.75-8.8%$3.96$1.62▼$5.05$135.86M2.19749,982 shs783,309 shsPEPGPepGen$1.93-8.1%$1.76$1.01▼$7.80$133.50M1.881.08 million shs734,799 shsRNXTRenovoRx$0.87+1.3%$0.90$0.70▼$1.45$38.98M0.99176,486 shs148,229 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLENZLENZ Therapeutics+8.51%+5.79%-1.70%-41.58%-83.42%NRXPNRx Pharmaceuticals-8.76%-12.18%+5.22%+27.55%+23.76%PEPGPepGen-8.10%-14.22%+8.73%+25.32%+32.19%RNXTRenovoRx+1.26%0.00%-9.20%+1.02%-31.87%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLENZLENZ Therapeutics$5.48+8.5%$6.26$4.68▼$50.40$171.82M0.621.07 million shs1.43 million shsNRXPNRx Pharmaceuticals$3.75-8.8%$3.96$1.62▼$5.05$135.86M2.19749,982 shs783,309 shsPEPGPepGen$1.93-8.1%$1.76$1.01▼$7.80$133.50M1.881.08 million shs734,799 shsRNXTRenovoRx$0.87+1.3%$0.90$0.70▼$1.45$38.98M0.99176,486 shs148,229 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLENZLENZ Therapeutics+8.51%+5.79%-1.70%-41.58%-83.42%NRXPNRx Pharmaceuticals-8.76%-12.18%+5.22%+27.55%+23.76%PEPGPepGen-8.10%-14.22%+8.73%+25.32%+32.19%RNXTRenovoRx+1.26%0.00%-9.20%+1.02%-31.87%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLENZLENZ Therapeutics 2.38Hold$29.80443.80% UpsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.25920.00% UpsidePEPGPepGen 2.71Moderate Buy$11.50495.85% UpsideRNXTRenovoRx 2.75Moderate Buy$8.50882.32% UpsideCurrent Analyst Ratings BreakdownLatest RNXT, LENZ, PEPG, and NRXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026RNXTRenovoRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/15/2026LENZLENZ Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/7/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/29/2026RNXTRenovoRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/17/2026LENZLENZ Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026PEPGPepGen Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.006/8/2026RNXTRenovoRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/2/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/1/2026RNXTRenovoRx Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.50 ➝ $14.005/21/2026PEPGPepGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/13/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$5.00 ➝ $4.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLENZLENZ Therapeutics$20.99M8.19N/AN/A$9.09 per share0.60NRXPNRx Pharmaceuticals$2.29M59.25N/AN/A($0.54) per share-6.94PEPGPepGenN/AN/AN/AN/A$2.14 per shareN/ARNXTRenovoRx$1.49M26.18N/AN/A$0.15 per share5.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLENZLENZ Therapeutics-$82.13M-$3.60N/AN/AN/A-519.30%-46.82%-43.32%7/29/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.09N/A6.36N/AN/AN/A-202.92%8/17/2026 (Estimated)PEPGPepGen-$89.65M-$1.75N/AN/AN/AN/A-59.89%-49.62%8/6/2026 (Estimated)RNXTRenovoRx-$11.17M-$0.33N/AN/AN/A-823.98%-135.03%-101.92%8/13/2026 (Estimated)Latest RNXT, LENZ, PEPG, and NRXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/17/2026Q2 2026NRXPNRx Pharmaceuticals-$0.09N/AN/AN/A$1.75 millionN/A8/13/2026Q2 2026RNXTRenovoRx-$0.08N/AN/AN/A$0.70 millionN/A8/6/2026Q2 2026PEPGPepGen-$0.30N/AN/AN/AN/AN/A7/29/2026Q2 2026LENZLENZ Therapeutics-$1.0505N/AN/AN/A$2.38 millionN/A5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/14/2026Q1 2026RNXTRenovoRx-$0.08-$0.08N/A-$0.09$0.47 million$0.56 million5/12/2026Q1 2026PEPGPepGen-$0.31-$0.26+$0.05-$0.26N/AN/A5/11/2026Q1 2026LENZLENZ Therapeutics-$1.10-$1.32-$0.22-$1.32$1.76 million$1.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLENZLENZ TherapeuticsN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ARNXTRenovoRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLENZLENZ TherapeuticsN/A10.4010.26NRXPNRx PharmaceuticalsN/A0.290.29PEPGPepGenN/A14.9814.98RNXTRenovoRxN/A7.156.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLENZLENZ Therapeutics54.32%NRXPNRx Pharmaceuticals4.27%PEPGPepGen58.01%RNXTRenovoRx3.10%Insider OwnershipCompanyInsider OwnershipLENZLENZ Therapeutics8.30%NRXPNRx Pharmaceuticals6.40%PEPGPepGen1.30%RNXTRenovoRx9.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLENZLENZ Therapeutics11031.35 million28.75 millionN/ANRXPNRx Pharmaceuticals236.23 million33.91 millionOptionablePEPGPepGen3069.17 million68.27 millionNot OptionableRNXTRenovoRx645.05 million40.82 millionNot OptionableRNXT, LENZ, PEPG, and NRXP HeadlinesRecent News About These CompaniesRenovoRx (NASDAQ:RNXT) Upgraded by Wall Street Zen to Sell RatingJuly 18, 2026 | americanbankingnews.comRenovoRx Stock Short Interest Report | NASDAQ:RNXT | BenzingaJuly 7, 2026 | benzinga.comRenovoRx Stockholders Approve Directors and Equity PlanJune 30, 2026 | tipranks.comRenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 TranscriptJune 23, 2026 | seekingalpha.comRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic CancerJune 11, 2026 | globenewswire.comAscendiant Remains a Buy on RenovoRx (RNXT)June 5, 2026 | theglobeandmail.comRenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rdJune 4, 2026 | globenewswire.comRenovoRx, Inc.: RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic CancerMay 28, 2026 | finanznachrichten.deRenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic CancerMay 28, 2026 | globenewswire.comRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual MeetingMay 26, 2026 | globenewswire.comMark Voll Buys 25,000 Shares of RenovoRx (NASDAQ:RNXT) StockMay 22, 2026 | insidertrades.comRenovoRx (RNXT) Q1 2026 Earnings TranscriptMay 19, 2026 | fool.comRenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20thMay 19, 2026 | globenewswire.comShaun Bagai, CEO of Renovorx, buys $0 of RNXT stockMay 18, 2026 | investing.comRenovoRx Inc (RNXT) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic ExpansionMay 15, 2026 | finance.yahoo.comRenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2026 | zacks.comRenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-QuarterMay 14, 2026 | finance.yahoo.comRenovoRx Inc (RNXT) Q1 2026 Earnings Report Preview: What To ExpectMay 14, 2026 | finance.yahoo.comRenovoRx, Inc. (RNXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseMay 7, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA)May 1, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNXT, LENZ, PEPG, and NRXP Company DescriptionsLENZ Therapeutics NASDAQ:LENZ$5.48 +0.43 (+8.51%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.44 -0.04 (-0.73%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.NRx Pharmaceuticals NASDAQ:NRXP$3.75 -0.36 (-8.76%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.80 +0.06 (+1.47%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.PepGen NASDAQ:PEPG$1.93 -0.17 (-8.10%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.98 +0.05 (+2.38%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.RenovoRx NASDAQ:RNXT$0.87 +0.01 (+1.26%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.86 0.00 (-0.03%) As of 07/24/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
